EU/3/03/177

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in June 2017 at the end of the period of market exclusivity.

On 12 December 2003, orphan designation (EU/3/03/177) was granted by the European Commission to Gregory Fryer Associates Ltd, United Kingdom, for 3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione for the treatment of multiple myeloma. The sponsorship was transferred to Celgene Europe Limited in July 2005.

3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione in treatment of multiple myeloma has been authorised in the EU as Revlimid since 14 June 2007.

This medicine is now known as lenalidomide.

Key facts

Active substance
3-(4'Aminoisoindoline-1'-one)-1-piperidine-2,6-dione (lenalidomide)
Medicine name
Revlimid
Disease / condition
Treatment of multiple myeloma
Date of decision
12/12/2003
Outcome
Withdrawn
Orphan decision number
EU/3/03/177

Sponsor's contact details

Celgene Europe Limited
1 Longwalk Road
Stockley Park
Uxbridge
Middlesex UB11 1DB
United Kingdom
Telephone: +44 208 831 83 00
Telefax: +44 208 831 83 01
E-mail: medinfo.uk.ire@celgene.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating